United Spirits Targets Craft Gin Takeover, Biocon Wraps QIP, and CONCOR Plans Bonus Bonanza

United Spirits has its eyes set on India’s growing premium spirits segment. Meanwhile, Biocon locks in funding through equity sales, CONCOR preps for a bonus party, and Uno Minda goes big on expansion. It’s been a packed week for India Inc.

United Spirits Eyes Full Control of NAO Spirits in ₹130 Crore Deal

United Spirits Ltd is making a spirited move — literally. The beverage giant has agreed to acquire the entire stake in NAO Spirits & Beverages Pvt Ltd at an enterprise value of ₹130 crore (roughly $15.2 million).

That’s 37,683 equity shares United Spirits is going after, aiming for full ownership of the craft gin maker that’s behind Greater Than and Hapusa — two of India’s top-shelf gin brands.

NAO Spirits has been riding the craft wave for a while, pushing Indian gin into the global spotlight. This deal signals a broader ambition by United Spirits to tighten its grip on the fast-growing premium alcohol market.

With India’s younger consumers increasingly turning to premium options over traditional ones like whisky or rum, this deal could be perfectly timed.

Biocon Closes ₹1,200 Crore QIP at a Discount

Biocon Ltd has officially wrapped up its Qualified Institutional Placement (QIP), pulling in capital by issuing shares at ₹300 apiece — a 3% discount to the floor price of ₹340.20.

The company confirmed that the issue was approved and completed on June 19, 2025. This capital raise is expected to strengthen Biocon’s balance sheet and support ongoing R&D efforts.

Here’s a quick breakdown:

QIP Price: ₹300 per share
Floor Price: ₹340.20 per share
Discount: 3%
Completion Date: June 19, 2025

Discounted or not, the move comes amid a wave of QIPs across pharma and biotech firms looking to fund expansion and drug pipeline development.

And yes, markets reacted mildly, with shares closing flat after the news broke — suggesting investors already saw this coming.

NATCO Pharma Gets a Clean Slate from USFDA

NATCO Pharma has completed a 10-day-long inspection by the USFDA at its Kothur, Hyderabad facility. The audit, which ran from June 9 through June 19, was part of the regular compliance cycle.

So far, the company hasn’t reported any major observations — which is usually good news in pharma speak.

It’s worth noting that this isn’t NATCO’s first tango with the FDA. The company has been through multiple rounds of scrutiny and has mostly come out clean, earning it credibility in global generics.

Given the FDA’s increasing strictness post-COVID, even a routine inspection that wraps without citations is a small win.

CONCOR Plans Bonus Share Issue; Record Date Set for July 4

CONCOR has fixed July 4, 2025, as the record date to determine which shareholders will be eligible for its upcoming bonus issue. The ratio? One new share for every four already held.

But wait — this isn’t a done deal yet. The proposal still needs shareholder approval, which the company expects to wrap up soon.

The proposed bonus could signal confidence in the company’s financials or simply a move to increase retail participation. Either way, the market usually likes these kinds of announcements.

It also sends a message — the company is in a position to reward its loyal investors.

Uno Minda to Invest ₹210 Crore in New Plant in Sambhajinagar

Uno Minda’s board committee has cleared the decks for a new manufacturing facility in Sambhajinagar, Aurangabad, with a project cost pegged at ₹210 crore.

The new plant is expected to add 3,629 metric tonnes (MT) of capacity per year, aimed to be achieved in phases. The company hasn’t disclosed exact phase-wise timelines yet, but the expansion hints at long-term demand visibility.

This move aligns with rising demand for auto components, especially in the two-wheeler and EV sectors, where Uno Minda has been actively building a foothold.

Here’s a quick look at the projected capacity and cost: